|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||0.0990 - 0.1040|
|52 Week Range||0.0350 - 0.6300|
|Beta (5Y Monthly)||7.89|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
MIAMI, Jun 15, 2021--Organicell announces positive results of their expanded access trial for the treatment of mild to moderate COVID-19 using Zofin.
Organicell launches a service platform for their first autologous product called Patient Pure X (PPX).
Organicell to present results of Zofin clinical studies at the International Society of Cell and Gene Therapy (ISCT) annual meeting.